Summary of findings: antibiotics probably leads to lower febrile patients and episodes compared with placebo or no intervention (moderate certainty).
Summary of findings: antibiotics leads to lower bacteraemia compared with placebo or no intervention (high certainty).
Summary of findings: quinolone prophylaxis probably leads to higher all cause‐mortality compared with TMP‐SMZ prophylaxis (moderate certainty).
Summary of findings: quinolone prophylaxis probably leads to lower febrile patients and episodes compared with TMP‐SMZ prophylaxis (moderate certainty).
Summary of findings: quinolone prophylaxis probably leads to lower bacteraemia compared with TMP‐SMZ prophylaxis (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings 2: PLD alone changes overall severe adverse events (grade > 3) compared with other conventional chemotherapy (very low certainty).
It is very uncertain whether summary of findings 2: PLD alone changes anaemia (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
It is very uncertain whether summary of findings 2: PLD alone changes hand‐foot syndrome (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
It is very uncertain whether summary of findings 2: PLD alone changes neurological (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).
It is very uncertain whether summary of findings 2: PLD alone changes progression‐free survival (PFS) compared with other conventional chemotherapy (very low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with chemotherapy (low certainty).
It is very uncertain whether summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… changes progression‐free survival (PFS) compared with chemotherapy (very low certainty).
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with placebo after chemotherapy (maintenance therapy) (moderate certainty).
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… leads to lower progression‐free survival (PFS) compared with placebo after chemotherapy (maintenance therapy) (high certainty).